Updated version 3 - Becton Dickinson commits to invest 19 billion dollars in an agreement with the government.
路透社2026/10/06 15:18BD will invest $3 billion to expand its manufacturing operations in the United States, aiming to increase the proportion of critical medical supplies sourced domestically to approximately 80%. The agreement links the company’s U.S. manufacturing commitments to tariff relief. Information about the stock price was added in the third paragraph, analyst commentary in the sixth paragraph, and background information in the eleventh paragraph. Siddhi Mahatole, Reuters, October 6 — Becton Dickinson and Company (BDX.N) has become the first major U.S. medical device manufacturer to sign an agreement with the U.S. government to expand domestic manufacturing, with a pledge to invest $19 billion in the coming years in exchange for protection against future tariffs. Under the agreement, the company said on Tuesday it plans to make capital, operational, and supply chain investments in the U.S., with $3 billion specifically allocated to strategic manufacturing facilities across the country. Shares of the medical device maker rose 2.4% in early trading. This deal is one of several measures by the Trump administration to encourage domestic healthcare manufacturing through the threat of tariffs, with several major pharmaceutical companies having already committed billions of dollars toward building and expanding production and R&D facilities in the U.S. The agreement ties BD’s U.S. manufacturing commitments to future exemptions from tariffs on related products and raw materials under Section 232, depending on the final scope of the measures and whether the company achieves agreed-upon milestones. Jefferies analyst Matthew Taylor commented, “We believe clarity on tariff policy, or tariff impacts being potentially ‘not as bad as feared,’ could be an inflection point for the medtech sector.” He added, “We are curious if there are more medtech-related announcements pending.” The company plans to increase annual U.S. production by around 5 billion basic medical supply units, raising the domestic supply share to roughly 80%. BD also intends to use U.S.-made steel to manufacture all needles for the U.S. market domestically. Becton Dickinson stated that, as the final tariff rates, product range, and implementation timelines remain undetermined, the financial impact of the agreement has not been quantified yet. This announcement builds on President Donald Trump’s Monday statement that the company has agreed to invest $3 billion to shift basic medical product manufacturing to the U.S., with more than $1 billion allocated to Nebraska. In January this year, Becton Dickinson announced a $110 million investment to expand the production of prefilled syringes and needles in Columbus, Nebraska, expected to create about 120 jobs. Syringe products are expected to start shipping to customers by mid-2026.
Stock price information added in paragraph 3, analyst commentary added in paragraph 6, background information added in paragraph 11
Siddhi Mahatole
Reuters, Oct 6 - Becton Dickinson and Company BDX.N became the first major U.S. medical device company to reach a deal with the U.S. government to expand domestic manufacturing, pledging to invest $19 billion over the coming years in exchange for relief from future tariffs.
Under the agreement, the company said on Tuesday it plans to make capital, operational, and supply chain investments in the U.S., with $3 billion dedicated specifically to strategic manufacturing sites across the country.
The medical device maker’s shares rose 2.4% in early trading.
The deal is one of the initiatives by the Trump administration (link) to use tariff threats to stimulate domestic healthcare manufacturing. A number of leading pharmaceutical firms have already pledged billions of dollars (link) to build and expand manufacturing and R&D facilities in the U.S.
The agreement ties BD’s U.S. manufacturing commitment to the exemption of tariffs on related products and raw materials under Section 232, depending on the final scope of measures and whether the company meets agreed milestone targets.
Jefferies analyst Matthew Taylor said, “We believe clarity on tariff policies, or if the ultimate tariff impact is ‘not as bad as feared’, could be an inflection point for the medtech sector.” He added, “We are curious whether more medtech announcements are in the pipeline.”
The company plans to increase annual U.S. production by about 5 billion basic medical supply items, raising its domestic supply share to roughly 80%.
The company also plans to use U.S.-made steel for all needles manufactured in the U.S. for the American market.
Becton Dickinson said that as the final tariff rates, product scope, and timeline for implementation are not yet determined, it has not quantified the financial impact of the agreement.
The announcement builds on President Donald Trump’s statement on Monday (link), saying the company had agreed to invest $3 billion to move production of basic medical products to the U.S., with over $1 billion going to Nebraska.
In January this year, Becton Dickinson had announced (link) it would invest $110 million in Columbus, Nebraska, to expand production of pre-filled syringes and needles, expected to create around 120 jobs, with the syringe products expected to be shipped to customers beginning mid-2026.
(To assist non-English speakers, Reuters provides automated translations of its reports in several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translation, and it is provided for reader convenience only. Reuters assumes no responsibility for any damage or loss arising from the use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The New Zealand Dollar edges off its low as the US Dollar slips
Encompass Health Opens Rehabilitation Hospital in Bangor, Maine
05:57 PM EDT, 10/06/2026 (MT Newswires) -- Encompass Health (EHC) said late Tuesday it has opened the Encompass Health Rehabilitation Hospital of Bangor in Bangor, Maine and the 50-bed inpatient rehabilitation hospital is now accepting patients. The hospital offers essential rehabilitation services to help patients recovering from strokes, brain injuries, spinal cord injuries, amputations and complex orthopedic conditions regain functional ability, independence and quality of life, the company said. Patients receive physical, occupational and speech therapy based on their individual needs.
Constellation Brands, the maker of Corona beer, exceeds market expectations in the second quarter thanks to strong demand
Reuters, October 6 - Constellation Brands (STZ.N) reported on Tuesday that its second-quarter profit and sales both exceeded market expectations, thanks to strong demand for its beer products such as Modelo Especial and Victoria, which effectively offset challenges facing the alcohol sector amid weak consumer sentiment. The company also announced that it had acquired SpikedAde, a ready-to-drink (RTD) company with vodka-based products, for at least $75 million, as part of its strategy to expand into new demand segments and strengthen its position in the fast-growing RTD category. Constellation Brands will pay $75 million upon the closing of the SpikedAde deal, and up to an additional $278 million over the next five years, depending on the brand’s performance and the company’s capital allocation priorities. The company’s beer business benefited this year from major sports events, as the FIFA World Cup and NBA Finals boosted viewing parties and social drinking occasions. According to data compiled by London Stock Exchange Group (LSEG), net sales for the quarter ended August 31 rose 6% to $2.63 billion, surpassing analysts’ average estimate of $2.54 billion. Adjusted earnings per share for the quarter were $3.74, above the expected $3.56. The wine and spirits business reported quarterly net sales growth of 17%, while beer increased by 5%. Constellation Brands reaffirmed its fiscal 2027 performance outlook: adjusted earnings per share between $11.20 and $11.90, with organic net sales expected to range from a 1% decline to a 1% increase. The company lowered its annual operating margin forecast from the previous 32%-33% range to between 31% and 32%. Its stock fell 4.5% in after-hours trading, with a year-to-date drop of about 16%. In April, the company withdrew its fiscal 2028 performance outlook, citing a turbulent operating environment and uncertain near-term prospects.
Kraft Heinz General Counsel Angel S. Willis resigns effective Oct. 20
Kraft Heinz EVP, Global General Counsel and Corporate Affairs Officer Angel S. Willis will resign effective Oct. 20, 2026. Willis notified the company on Oct. 2, 2026, citing plans to pursue other opportunities. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Kraft Heinz Company published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001637459-26-000067), on October 06, 2026, and is solely responsible for the information contained therein.
Crypto prices
More
